lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
=== Improvements in forensics === With the advent of and improvements to DNA testing/DNA profiling and other forensics technology, many cold cases are being re-opened and prosecuted. Police departments are opening cold case units whose job is to re-examine cold case files. DNA evidence helps in such cases but as in the case of fingerprints, it is of no value unless there is evidence on file to compare it to. However, to combat that issue, the FBI is switching from using the Integrated Automated Fingerprint Identification System (IAFIS) to using a newer technology called the Next Generation Identification (NGI). Other improvements in forensics lie in fields such as:
The R1 plasmid is a plasmid that was first isolated from Salmonella paratyphi bacteria in 1963. It is a short plasmid, composed of 97,566 nucleotides and 120 genes, that belongs to the IncFII plasmid group. There are about one to two copies of the R1 plasmid per chromosome. The R1 plasmid imparts multi-drug antibiotic resistance to its host bacteria. The "R" in "R1" stands for "resistance", and the R1 plasmid contains resistance factors, or R factors, giving it the power to resist certain antibiotics. It's known as a "low copy" plasmid, meaning that it exists in relatively few copies in any given bacteria. This characteristic allows the R1 plasmid to have an efficient plasmid stabilization system, that aids in stabilizing medium copy number plasmids. R1 must rely on a "Type II" segregation system. This plasmid system ensures that at least one copy is contained in each daughter cell after cell division.
Blue Ribbon Panel reports are addressed to the NIH Director, the Advisory Committee of the Director, and the IC Director. In addition to the external NIH Boards of Scientific Counselors and Blue Ribbon Panels, the NIH IRP receives regular and periodic independent evaluations by the following external bodies:
Sources: en.wikipedia.org
In order to successfully complete a fermentation with minimum to no negative attributes being added to the wine, yeast needs to have the full assortment of its nutritional needs met. These include not only an available energy source (carbon in the form of sugars such as glucose) and yeast assimilable nitrogen (ammonia and amino acids or YAN) but also minerals (such as magnesium) and vitamins (such as thiamin and riboflavin) that serve as important growth and survival factors. Among the other nutritional needs of wine yeast:
β-Carotene (beta-carotene) is an organic, strongly colored red-orange pigment abundant in fungi, plants, and fruits. It is a member of the carotenes, which are terpenoids (isoprenoids), synthesized biochemically from eight isoprene units and thus having 40 carbons. Dietary β-carotene is a provitamin compound, converting in the body to retinol (vitamin A). In foods, it has rich content in carrots, pumpkin, spinach, and sweet potato. It is used as a dietary supplement and may be prescribed to treat erythropoietic protoporphyria, an inherited condition of sunlight sensitivity. β-carotene is the most common carotenoid in plants. When used as a food coloring, it has the E number E160a. The structure was deduced in 1930. Isolation of β-carotene from fruits abundant in carotenoids is commonly done using column chromatography. It is industrially extracted from richer sources such as the algae Dunaliella salina. The separation of β-carotene from the mixture of other carotenoids is based on the polarity of a compound. β-Carotene is a non-polar compound, so it is separated with a non-polar solvent such as hexane. Being highly conjugated, it is deeply colored, and as a hydrocarbon lacking functional groups, it is lipophilic.
== Album information == Wolf Hoffmann explained the concept behind the album: "We had read an article that someone was working on an artificial heart and that one day everybody is going to have a computerized heart. It talked, in general terms, about how more and more of humanity gets sucked out of daily life and more and more replaced by machines. It's not a new thing now, but then it was new. Humans versus machine was the general vibe of the record." The original cover concept was for a hologram of a metal heart until budget considerations resulted in a traditional cover. But fittingly for the futuristic theme of the album, Metal Heart was the first Accept album to be digitally mastered. Hoffmann recalls Dieter Dierks as a very demanding producer: "We would do some pieces several dozen times trying to capture what he had in his mind for a specific section," adding: "Each song we tried different combinations of guitars, mic'ing and even strings!" The song "Metal Heart" is well known for containing the cover of two famous classical themes: Tchaikovsky's "Slavonic March" (in the intro) and Beethoven's "Für Elise" in the main riff and solo. This song was covered in 1998 by Norwegian black metal band Dimmu Borgir for their album Godless Savage Garden. "I had no idea it would become as popular as it did," Hoffmann remembers of his contribution to the song. "Midnight Mover", about a drug dealer, is one of the more commercial songs on the album and was selected for a music video that anticipates the bullet time filming technique by a full decade.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.